A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology

Xiaoxi Xu, Rajendra Kumari, Jun Zhou, Jing Chen, Binchen Mao, Jingjing Wang, Meiling Zheng, Xiaolong Tu, Xiaoyu An, Xiaobo Chen, Likun Zhang, Xiaoli Tian, Haojie Wang, Xin Dong, Zhengzheng Bao, Sheng Guo, Xuesong Ouyang, Limei Shang, Fei Wang, Xuefei YanRui Zhang, Robert G J Vries, Hans Clevers, Qi-Xiang Li

Onderzoeksoutput: Bijdrage aan wetenschappelijk tijdschrift/periodieke uitgaveArtikelWetenschappelijkpeer review

5 Citaten (Scopus)


Patient-derived tumor xenograft (PDX)/organoid (PDO), driven by cancer stem cells (CSC), are considered the most predictive models for translational oncology. Large PDX collections reflective of patient populations have been created and used extensively to test various investigational therapies, including population-trials as surrogate subjects in vivo. PDOs are recognized as in vitro surrogates for patients amenable for high-throughput screening (HTS). We have built a biobank of carcinoma PDX-derived organoids (PDXOs) by converting an existing PDX library and confirmed high degree of similarities between PDXOs and parental PDXs in genomics, histopathology and pharmacology, suggesting "biological equivalence or interchangeability" between the two. Here we demonstrate the applications of PDXO biobank for HTS "matrix" screening for both lead compounds and indications, immune cell co-cultures for immune-therapies and engineering enables in vitro/in vivo imaging. This large biobank of >550 matched pairs of PDXs/PDXOs across different cancers could become powerful tools for the future cancer drug discovery.

Originele taal-2Engels
Pagina's (van-tot)e0279821
TijdschriftPLoS ONE
Nummer van het tijdschrift1
StatusGepubliceerd - 2023


Duik in de onderzoeksthema's van 'A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology'. Samen vormen ze een unieke vingerafdruk.

Citeer dit